Key Takeaways
- • Former FDA Commissioner Stephen Hahn joined Flagship Pioneering as chief medical officer to lead its Preemptive Medicine & Health Security initiative, effective June 2021.
- • Hahn served as FDA commissioner from 2019 to 2021 under the Trump administration and directly oversaw emergency use authorizations for both Moderna and Pfizer COVID-19 vaccines in December 2020.
- • Flagship Pioneering is the venture capital firm that launched Moderna approximately a decade prior and has generated substantial returns from the company's coronavirus vaccine commercialization.
- • Hahn's appointment signals institutional focus on preemptive medicine and health security as growth areas, with Flagship CEO Noubar Afeyan emphasizing pandemic-driven investment momentum in these sectors.
- • The move represents a transition from regulatory oversight to venture capital strategy, leveraging Hahn's clinical background as a radiation oncologist and his regulatory expertise in therapeutics, vaccines, devices, diagnostics, and clinical trials.
Summary
Stephen Hahn, who served as Food and Drug Administration Commissioner from 2019 to 2021 during the Trump administration, has joined Flagship Pioneering as chief medical officer. In this role, Hahn will lead the venture capital firm's Preemptive Medicine & Health Security initiative, effective June 15, 2021.
During his tenure at the FDA, Hahn oversaw regulatory affairs across COVID and non-COVID portfolios, with particular responsibility for therapeutics, vaccine development, devices, diagnostics, and clinical trials. Most notably, he directed the FDA's emergency use authorization process for both the Moderna and Pfizer COVID-19 vaccines in December 2020, a regulatory milestone during the height of the pandemic response.
Flagship Pioneering, founded by Noubar Afeyan, is the venture capital firm that launched Moderna approximately a decade earlier and has benefited substantially from the company's vaccine commercialization success. In announcing Hahn's appointment, Afeyan stated that the pandemic "brought into stark focus how important it is to bring increased attention and investment to our health security globally, and to preemptive medicine more broadly." Afeyan added that Flagship would "benefit from Steve's clinical and administrative leadership in helping us dimension and pursue our growing number of explorations and companies in this emerging field."
Hahn, a radiation oncologist by training, characterized his career primarily as one of clinical practice and research. He stated that "it is an honor to join Flagship Pioneering in its efforts to prioritize innovation" and emphasized that "the importance of investing in innovation and preemptive medicine has never been more heightened." The appointment reflects Flagship's strategic pivot toward health security and preventive medicine sectors, leveraging Hahn's dual expertise in clinical medicine and regulatory governance.
During his tenure at the FDA, Hahn oversaw regulatory affairs across COVID and non-COVID portfolios, with particular responsibility for therapeutics, vaccine development, devices, diagnostics, and clinical trials. Most notably, he directed the FDA's emergency use authorization process for both the Moderna and Pfizer COVID-19 vaccines in December 2020, a regulatory milestone during the height of the pandemic response.
Flagship Pioneering, founded by Noubar Afeyan, is the venture capital firm that launched Moderna approximately a decade earlier and has benefited substantially from the company's vaccine commercialization success. In announcing Hahn's appointment, Afeyan stated that the pandemic "brought into stark focus how important it is to bring increased attention and investment to our health security globally, and to preemptive medicine more broadly." Afeyan added that Flagship would "benefit from Steve's clinical and administrative leadership in helping us dimension and pursue our growing number of explorations and companies in this emerging field."
Hahn, a radiation oncologist by training, characterized his career primarily as one of clinical practice and research. He stated that "it is an honor to join Flagship Pioneering in its efforts to prioritize innovation" and emphasized that "the importance of investing in innovation and preemptive medicine has never been more heightened." The appointment reflects Flagship's strategic pivot toward health security and preventive medicine sectors, leveraging Hahn's dual expertise in clinical medicine and regulatory governance.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.